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Abstract
Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity as compared to
their sporadic counterparts. Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized
by deficient homologous recombination (HR) of DNA, that makes them particularly sensitive to platinum
compounds or inhibitors of poly (ADP-ribose) polymerase (PARP). Outstandingly durable complete responses to
high dose chemotherapy have been observed in several cases of BRCA-related metastatic breast cancer (BC).
Multiple lines of evidence indicate that women with BRCA1-related BC may derive less benefit from taxane-based
treatment than other categories of BC patients. There is virtually no reports directly assessing drug response in
hereditary colorectal cancer (CRC) patients; studies involving non-selected (i.e., both sporadic and hereditary) CRC
with high-level microsatellite instability (MSI-H) suggest therapeutic advantage of irinotecan. Celecoxib has been
approved for the treatment of familial adenomatous polyposis (FAP). Hereditary medullary thyroid cancers (MTC)
have been shown to be highly responsive to a multitargeted tyrosine kinase inhibitor vandetanib, which exerts
specific activity towards mutated RET receptor. Given the rapidly improving accessibility of DNA analysis, it is
foreseen that the potential predictive value of cancer-associated germ-line mutations will be increasingly
considered in the future studies.
Introduction
Search for hereditary cancer genes was always regarded
as a high priority translational research with immediate
health impact. It was foreseen, that the discovery of
tumor predisposing mutations and the development of
appropriate genetic tests will allow identifying yet
healthy subjects, who are at nearly fatal risk of specific
type of cancer and thus may benefit from a timely medi-
cal intervention. Since the discovery of major cancer
genes in the mid 1990s, thousands of mutation carriers
have been subjected to intensive surveillance programs
in order to secure early diagnosis of the disease [1]. The
preventive surgery has been applied in some instances,
that led to a proven reduction of cancer-specific mortal-
ity [2]. While the initial practical focus of cancer genetic
research was limited to various aspects of cancer detec-
tion and prevention, it is now getting increasingly recog-
nized that hereditary tumors may have distinct
bioclinical characteristics and thus require tailored treat-
ment strategies.
Breast-ovarian cancer syndrome
The best-known hereditary cancer genes, BRCA1 and
BRCA2, contribute to substantial share of breast and
ovarian tumor incidence around the globe, and have
been studied with significant level of comprehension [3].
Mutations in other relevant genes, such as CHEK2,
P A L B 2( F A N C N ) ,A T M ,N B N( N B S 1 ) ,B R I P 1( F A N C J ,
BACH1), BLM, are less frequent and have not been sub-
jected yet to systematic clinical studies.
BRCA1 and BRCA2
BRCA1 and BRCA2 genes play a central role in the
repair of double-strand DNA breaks by homologous
recombination (HR). Cancers in BRCA heterozygous
individuals arise due to somatic inactivation of the
remaining wild-type allele of the gene. This provides a
critical biological difference between cancerous and nor-
mal cells: while BRCA-driven tumors are characterized
by HR deficiency, normal tissues from the same indivi-
duals retain non-affected BRCA allele and the ability to
cope with DNA damage [4,5]. Although BRCA1-a n d
BRCA2-related cancers demonstrate somewhat distinct
picture of genetic abnormalities [6,7], they both have
increased number of gross chromosomal aberrations
and therefore higher tumor grade [8-11]. Cells carrying
multiple genetic lesions due to HR defect are normally
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convincing evidence from both human studies and mur-
ine models that p53 inactivation is an absolute prerequi-
site for the propagation of BRCA-dysfunctional tumors
cells [12-15].
BRCA1 has a wider spectrum of functions than
BRCA2 [16,17]. In addition to DNA repair, BRCA1 is
involved in breast cell differentiation and transcriptional
regulation of the estrogen receptor (ER) [18]. It has
been repeatedly shown, that the majority of BRCA1-
mutated breast carcinomas (BC) do not express ER,
while the hormonal receptor pattern in BRCA2-asso-
ciated BC is similar to sporadic cases [19]. BRCA1 is
also essential for the mitotic spindle checkpoint as it
triggers cellular suicide in response to microtubule
damage [20].
Preclinical studies
A large number of preclinical studies aimed to assess
specific sensitivity of BRCA1- and BRCA2-defective cells
to various anticancer agents. Surprisingly, while the
effect of individual compounds has been repeatedly eval-
uated in diverse model systems (Table 1), there was vir-
tually no attempt to compare clinically relevant
combinations of the drugs (Table 2). This may consti-
tute a critical gap between preclinical and clinical
research, as single-agent therapy is almost never used as
initial treatment of breast or ovarian cancers. It is highly
likely, that the standard combinations of cytotoxic com-
pounds produce distinct spectrum of DNA lesions and
therefore mediate distinct responses of BRCA-deficient
cells when compared to the same drugs acting alone.
There is an excellent consistency in the literature
regarding high sensitivity of both BRCA1-a n dBRCA2-
deficient cells to cisplatin and other platinum derivatives
[21-40]. It is believed that the DNA crosslinks caused by
platinating agents ultimately require homologous recom-
bination to correctly repair DNA damage, so the BRCA-
inactive cells cannot cope with this class of drugs. Simi-
lar consistency has been observed for another DNA-
crosslinking agent, mitomycin C [28,33,36,41-44].
Controversial data have been obtained for doxorubicin,
a widely used anthracycline antibiotic with multiple
mechanisms of action. Doxorubicin causes double-strand
breaks in the target DNA, so it may be particularly effec-
tive for the cells lacking error-free repair of this type of
lesion. Some investigations demonstrated high sensitivity
of BRCA-deficient cells to doxorubicin [24,45,46], while
other reports described entirely opposite findings [26, 33,
34. 36]. Another topoisomerase II inhibitor, etoposide,
showed selective efficacy against BRCA-defective cell in
all but one studies [23-25,36,47,48].
Analysis of microtubule poisons produced even more
complicated picture. It has been repeatedly demon-
strated that BRCA1-deficient cells are significantly less
sensitive to taxanes or vinca alkaloids than cells with
preserved BRCA1 function [23,25,26,49-51]. Although
these observations are in good agreement with the
established role of BRCA1 in cellular response to micro-
tubule damage [20], one cannot ignore the existence of
sound contradictory data. Zhou et al. [52] reported
increased sensitivity of BRCA1-mutated ovarian cancer
(OC) cell line to paclitaxel as compared to isogenic cells
with reconstituted BRCA1 f u n c t i o n .T a s s o n ee ta l .[ 5 3 ]
showed high sensitivity of BRCA1-deficient breast can-
cer cells to vinorelbine and argued that the differences
in the mechanism of action between various microtu-
bule interfering drugs have to be considered while inter-
preting the results of BRCA1 studies. DeLigio and Zorio
[20] commented that the tissue origin of the BRCA1-
mutated cells may be essential in determining the
response to taxanes and vinca alkaloids. BRCA2 preclini-
cal studies suggested little impact of the status this gene
in determining the response to microtubule interfering
agents [27,33,46,47].
Alkylating agents are almost always included in the
standard schemes for the treatment of breast and ovar-
ian cancers. Surprisingly, this class of drugs has not
been subjected to systematic studies in BRCA-deficient
model systems. Single-agent cyclophosphamide showed
only slight antitumor activity against BRCA1-mutated
human breast cancer xenografts growing in nude mice
[31]. At the same time, high-throughput pharmaceutical
screen involving BRCA2-deficent vs. BRCA2-proficient
mouse mammary tumor cell lines identified alkylating
agents (chlorambucil, melphalane, nimustine) as the
most potent and specific inhibitors of cell growth;
furthermore, high efficacy of these drugs was confirmed
in animal experiments [38].
Topoisomerase I inhibitors are rarely used for the
treatment of breast cancer, but included in some thera-
peutic schemes for ovarian cancer. High sensitivity to
these drugs was suggested for both BRCA1- [24,54] and
BRCA2-defective cells [38,46,55], although controversial
results have been reported as well [27].
There is a good agreement in the literature that sin-
gle-agent antimetabolites, 5-fluorouracil and gemcita-
bine, do not exert specific action against BRCA-deficient
tumors [24,33,46]. In contrast, 6-thioguanine was identi-
fied by a chemical library screen as the most potent
antagonist of BRCA2-mutated cells [46].
There is a growing number of studies demonstrating
pronounced efficacy of specific inhibitors of poly (ADP-
ribose) polymerase (PARP) against BRCA-deficient can-
cers [31,33,38-40,56-60]. It is suggested that inactivation
of PARP interferes with the repair of spontaneous DNA
single-strand breaks. In the normal cells these lesions
are converted to double-strand breaks during DNA
replication and then eliminated by homologous
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Study Study design and main findings
BRCA1
Husain et al. [21] Antisense inhibition of BRCA1 expression in the cisplatin-resistant clone of SKOV3 ovarian cancer cell line restored
sensitivity to the drug.
Bhattacharyya et al. [22] BRCA1-deficient mouse embryonic stem cells were more sensitive to cisplatin than isogenic BRCA1-proficient cells,
as determined by a clonogenic assay.
Brodie et al. [45] Cell lines, which were generated from mammary tumors growing in genetically engineered BRCA1-deficient mice,
demonstrated high sensitivity to doxorubicin in a cell survival assay.
Lafarge et al. [23] Inhibition of BRCA1 expression in HBL100 breast cancer cells led to increased sensitivity to cisplatin and
etoposide, but resistance to paclitaxel and vincristine, as assessed by the rhodamine B proliferation test.
Moynahan et al. [42] Increased sensitivity of BRCA1-deficient mouse embryonic stem cells to mitomycin C in a clonogenic assay;
reversed upon correction of BRCA1-mutated allele by gene targeting.
Mullan et al. [49] Tetracycline regulated inducible expression of BRCA1 in MBR62-bcl2 breast cancer cell line increased sensitivity to
paclitaxel and vincristine, by did not affect the response to cisplatin, doxorubicin, cyclophosphamide, 5-
fluorouracil, or bleomycin, as determined by a clonogenic assay.
Fedier et al. [24] Increased sensitivity of BRCA1-deficient mouse embryonic cells to the antiproliferative effect of camptothecin,
topotecan, doxorubicin, mitoxantrone, etoposide, carboplatin, oxaliplatin, but not of 5-fluoroucil, gemcitabine,
paclitaxel, docetaxel; increased apoptosis in response to doxorubicin but not to docetaxel.
Quinn et al. [25] BRCA1-deficiency is associated in increased sensitivity to apoptosis caused by etoposide, bleomycin or cisplatin,
but resistance to apoptotic response to paclitaxel or vinorelbine.
Tassone et al. [26] BRCA1-mutant HCC1937 breast cancer cells were more sensitive to cisplatin, but less sensitive to doxorubicin and
paclitaxel, than BRCA1-proficient MCF7 and MDA-MB-231 cells, as determined by the MTT test. Transfection of the
wild-type BRCA1 in HCC1937 cells decreased their sensitivity to cisplatin, but restored sensitivity to doxorubicin
and paclitaxel; this effect was at least in part attributed to the modulation of the apoptotic response.
Zhou et al. [52] SNU251 ovarian cancer cell line carrying truncation of 49 C-terminal aminoacids of the BRCA1 gene (partial
deletion of 2
nd BRCT domain) demonstrated increased sensitivity to paclitaxel in a cell viability assay; this effect
was reversed by the introduction of the wild-type BRCA1.
Farmer et al. [57] siRNA directed or chemical inhibition of PARP profoundly inhibited clonogenicity of BRCA1-deficient mouse
embryonic stem cells as compared to BRCA1-proficient isogenic cell lines; similar results were obtained upon
simultaneous inhibition of BRCA1 and PARP in MCF7 breast cancer cell line. This effect was attributed to the
massive growth arrest and subsequent apoptosis.
Tassone et al. [53] BRCA1-mutant HCC1937 breast cancer cells were more sensitive to vinorelbine than BRCA1-proficient MCF7 and
MDA-MB-468 cells; when docetaxel was used, HCC1937 were similarly sensitive as compared to MCF7, and less
sensitive than MDA-MB-468 (MTT test). Transfection of the wild-type BRCA1 in HCC1937 cells rendered resistance
to vinorelbine, but slightly increased sensitivity to docetaxel. The effect of vinorelbine was at least in part
attributed to the modulation of the apoptotic response.
Yun et al. [44] BRCA1-deficient mouse embryonic fibroblasts were significantly more sensitive to mitomycin C than BRCA1-wild-
type expressing isogenic cells, as demonstrated by a clonogenic assay. The effect of mitomycin C is mediated
through massive S-phase arrest followed by apoptosis.
Bartz et al. [29] BRCA1 inhibition strongly increased sensitivity of HeLa cells to cisplatin, as revealed by siRNA screen.
Chabalier et al. [50] siRNA-directed inactivation of BRCA1 function in MCF7 breast cancer cells rendered resistance to paclitaxel-
induced growth inhibition and mitotic arrest.
Xing and Orsulic [30] BRCA1-deficient transformed mouse ovarian surface epithelial cell lines demonstrated higher sensitivity to
cisplatin as compared to BRCA1-proficient isogenic cells, while no differential sensitivity to paclitaxel was
observed.
Donawho et al. [31] Veliparib potentiated inhibitory effect of cisplatin, carboplatin and cyclophosphamide towards human BRCA1-
mutated breast cancer xenografts (MX-1) growing in immunocompromised mice.
Rottenberg et al. [32] Doxorubicin, docetaxel and cisplatin inhibited growth of mammary tumors in genetically engineered BRCA1-
deficient mice. Treated tumors eventually acquired resistance to doxorubicin and docetaxel, but not to cisplatin.
Treszezamsky et al. [48] BRCA1-mutant HCC1937 breast cancer cells showed increased sensitivity to etoposide as compared to BRCA1-
wild-type expressing isogenic cells, as shown by a clonogenic assay.
Yamane et al. [117] BRCA1-mutant HCC1937 breast cancer cell line showed increased survival and decreased apoptosis in response 6-
thioguanine as compared to BRCA1-wild-type expressing isogenic cells.
Shafee et al. [34] Cisplatin caused marked regression of BRCA1-deficient tumors growing in genetically engineered mice, while
doxorubicin exerted only marginal effect.
Rottenberg et al. [59] Olaparib inhibited growth of mammary tumors in genetically engineered BRCA1-deficient mice. Combination of
olaparib with cisplatin or carboplatin produced longer recurrence-free and overall survival than olaparib alone.
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Promkan et al. [51] shRNA-directed inhibition of BRCA1 expression in MCF7 and MDA-MB-231 breast cancer cells decreased
cytotoxicity of paclitaxel. Breast cancer cell lines carrying BRCA1 mutation (HCC1937 and MDA-MB-436) also
demonstrated low sensitivity to paclitaxel.
Santarosa et al. [36] Antisense inhibition of BRCA1 expression in HBL100, MCF7 and T47D breast cancer cells led to increased
sensitivity to mitomycin C and cisplatin, but not to doxorubicin and etoposide, as determined by a clonogenic
assay. Similar results were obtained on the BRCA1-mutated HCC1937 breast cancer cell line. This effect was
attributed to premature senescence of the chemosensitive cells.
Tassone et al. [37] Cisplatin induced almost complete growth inhibition of HCC1937-derived (BRCA1-mutated) breast cancer
xenografts, while BRCA1-reconsituted HCC1937 xenografted tumors showed only partial response to cisplatin
treatment.
Zander et al. [54] Topotecan inhibited growth of mammary tumors in genetically engineered BRCA1-deficient mice.
Drew et al. [39] AG014699 (PARP inhibitor) was highly cytotoxic against breast cancer cells with mutationally inactivated (MDA-
MB-436) or epigenetically silenced (UACC3199) BRCA1, as determined by a clonogenic assay. BRCA1-deficient
HCC1937 cells were more sensitive to AG014699 than the isogenic cell line with restored BRCA1 function
(rhodamine B proliferation test). AG014699 and carboplatin efficiently inhibited growth of MDA-MB-436 and
UACC3199 derived xenografted tumors.
Goldberg et al. [60] Nanoparticle-mediated delivery of PARP1-specific siRNA inhibited growth of BRCA1-deficient mouse ovarian
cancer allografts; this effect was at least in part attributed to apoptotic death of targeted cells.
BRCA2
Abbott et al. [47] Increased sensitivity of BRCA2-deficient pancreatic cancer cell line CAPAN1 to mitoxantrone, etoposide and
amsacrine, but not to paclitaxel, as assessed by a cell survival assay. Antisense down-regulation of BRCA2 in
BRCA2-proficient pancreatic cancer cells resulted in hypersensitivity to mitoxantrone. CAPAN1 xenografted tumors
showed nearly complete response to mitoxantrone and marked response to etoposide.
Yu et al. [41] Increased sensitivity of BRCA2-deficient vs. BRCA2-wild-type mouse lymphocytes to the mitomycin C, as
determined by a cell survival assay.
Rahden-Staron et al, [55] Increased sensitivity of BRCA2-deficient Chinese hamster VS8 fibroblasts to camptothecin in a cell survival assay.
Samouelian et al. [27] Increased sensitivity of BRCA2-deficient ovarian cancer cell line TOV81 to cisplatin, but not to camptothecin or
paclitaxel, as assessed by a cell survival assay.
van der Heijden et al. [28] Increased sensitivity of BRCA2-deficient pancreatic cancer cell line CAPAN1 to cisplatin and mitomycin C, as
shown by a cell survival assay. Increased sensitivity to mitomycin C induced G2/M cell cycle growth arrest.
Bryant et al. [56] Chemical inhibition of PARP profoundly inhibited clonogenicity of BRCA2-deficient Chinese hamster VS8
fibroblasts as compared to parental V79 cells. Similar results were obtained upon simultaneous inhibition of
BRCA2 and PARP in MCF7 and MDA-MB-231 breast cancer cell lines.
Farmer et al. [57] siRNA directed or chemical inhibition of PARP profoundly inhibited clonogenicity of BRCA2-deficient mouse
embryonic stem cells as compared to BRCA2-proficient isogenic cell lines; similar results were obtained on BRCA2-
deficient Chinese hamster ovarian cancer cell line. This effect was attributed to the massive growth arrest and
subsequent apoptosis. Chemical PARP inhibitor suppressed growth of BRCA2-deficient xenografts in athymic
mice.
Gallmeier and Kern [155],
McCabe et al. [58]
BRCA2-deficient CAPAN1 pancreatic cancer cells were sensitive to highly active PARP inhibitors, while moderately
active PARP inhibitors did not affect cell survival.
van der Heijden et al. [43] BRCA2-deficient CAPAN1 xenografted tumors showed marked response to mitomycin C.
Bartz et al. [29] BRCA2 inhibition strongly increased sensitivity of HeLa cells to cisplatin, as revealed by siRNA screen.
Treszezamsky et al. [48] BRCA2-deficient EUFA423 fibroblasts showed increased sensitivity to etoposide as compared to BRCA1-wild-type
expressing isogenic cells, as shown by a clonogenic assay.
Evers et al. [33] Olaparib, cisplatin, mitomycin C and temozolomide effectively inhibited growth of BRCA2-deficent vs. BRCA2-
proficient mouse cell lines, while doxorubicin, docetaxel and 5-fluorouracil showed no difference. Synergism
between olaparib and cisplatin was observed for BRCA2-deficient but not for BRCA2-proficient cells.
Hay et al. [35] BRCA2-deficient mammary tumors growing in genetically engineered mice demonstrated high sensitivity to
olaparib and carboplatin.
Evers et al. [38] High-throughput pharmaceutical screen involving BRCA2-deficent vs. BRCA2-proficient mouse mammary tumor
cell lines identified alkylating agents (chlorambucil, melphalane, nimustine) as the most potent and specific
inhibitors of cell growth; differential inhibition was also registered for carboplatin, camptothecin and ellipticine.
BRCA2-deficient mammary tumors, either transplanted or growing in genetically engineered mice, demonstrated
high sensitivity to alkylating compounds. Synergistic interaction between alkylators and olaparib was observed
both in vitro and in vivo.
Issaeva et al. [46] Chemical library screen identified 6-thioguanine as the most potent inhibitor of the survival of BRCA2-deficient
human sarcoma U2OS cells and Chinese hamster VS8 fibroblasts. High efficacy of both 6-thioguanine and
AG014699 (PARP inhibitor) against BRCA2-deficient xenografted tumors. Comparison of BRCA2-deficient VS8 cells
versus isogenic BRCA2-expressing VS8+B2 cells: higher sensitivity to temozolomide, camptothecin and
doxorubicin, but lower sensitivity to gemcitabine and paclitaxel.
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HR due to loss of both alleles of either BRCA1 or
BRCA2, they cannot eliminate double-strand breaks by
error-free mechanism. As result, cancers arising in
BRCA carriers are selectively sensitive to PARP inhibi-
tors, while the normal tissues from the same individuals
retain a non-affected BRCA allele and are therefore cap-
able to compensate the consequences of decreased
PARP activity [61,62]. PARP inhibitors appear to be the
only class of drugs which was assessed in preclinical
models in combination with other anticancer agents;
synergism of PARP with platinum compounds and alky-
lating agents has been reported [31,33,38,39,59].
Breast cancer
T h em a j o r i t yo fBRCA2- and a certain fraction of
BRCA1-related BC express estrogen and/or progesterone
receptors and are therefore expected to benefit from
endocrine therapy. While a couple of studies examined
the chemopreventive impact of tamoxifen or oophorect-
omy in BRCA carriers [63] and some investigators ana-
lyzed benefits from the adjuvant use of estrogen
antagonists [64], there is no reports assessing the role of
BRCA status in determining the effect of endocrine
intervention in neoadjuvant or metastatic setting.
Data on the efficacy of conventional chemotherapeutic
schemes in BRCA-related vs. sporadic breast cancers are
summarized in the Table 2. Several research groups
reported outcomes of anthracycline-based therapy. Dela-
goge et al. [65], Chappuis et al. [66], Warner et al. [67],
H u b e r te ta l .[ 6 8 ] ,F o u r q u e te ta l .[ 6 9 ]a n dB y r s k ie ta l .
[70] provided evidence for remarkable sensitivity of
BRCA1/2-related cancers to the neoadjuvant anthracy-
cline-containing regimens. Interestingly, Hubert et al.
[68] and Wong Wong Keet et al. [71] observed worse
outcomes in BRCA2 vs. BRCA1 carriers. The data of
Petit et al. [72] are in strong disagreement with the
above observations: in their study only 2/12 (17%) of
BRCA1 carriers receiving 5-fluorouracil, epirubicin and
cyclophosphamide achieved pathologic complete
response (pCR), while pCR was detected in 21/43 (49%)
sporadic triple-negative BC.
The only available study of metastatic BC included
patients treated by either anthracycline-based or CMF
(CMF-like) therapy [73]. In contrast to neoadjuvant ser-
i e so fH u b e r te ta l .[ 6 8 ]a n dW o n gW o n gK e e te ta l .
[71], significantly improved outcomes were detected in
BRCA2 but not BRCA1 carriers. Low efficacy of CMF
therapy in BRCA1-related BC was also described by
Byrski et al. [70].
Several investigators analyzed the use of taxane-con-
taining schemes. Byrski et al. [70] observed low rate of
pCR in patients with BRCA1-mutated BC receiving
neoadjuvant combination of doxorubicin and docetaxel.
Moiseyenko et al. [74] reported lack of response of che-
monaive triple negative BRCA1-linked BC to the epiru-
bicin-docetaxel doublet. Wysocki et al. [75] genotyped
19 non-responders to docetaxel and revealed as many as
5 (26%) BRCA1 carriers. Kriege et al. [76] confirmed
poor efficacy of docetaxel in BRCA1 carriers, while
BRCA2-related BC did not fare worse as compared to
sporadic controls. It appears, that the preclinical and
clinical evidence warning against the early use of taxanes
for the treatment of BRCA1-related subtype of BC has
already achieved a critical threshold; probably, specifi-
cally designed retrospective studies assessing BRCA1 sta-
tus in distinct categories of taxane users may accelerate
further understanding of this issue [77].
The experience of the use of single-agent cisplatin for
the treatment of hereditary BC is still limited to BRCA1
carriers. Byrski et al. [70] reported 10/12 (83%) pCR in
patients undergoing neoadjuvant treatment. Silver et al.
[78] used cisplatin for the preoperative treatment of tri-
ple-negative BC; both BRCA1 carriers included in the
study demonstrated pCR. Moiseyenko et al. [74]
observed major response to cisplatin in a patient whose
metastatic BC was insensitive to the upfront anthracy-
cline-taxane combination. The development of resis-
tance to cisplatin may involve the appearance of
Table 1 Drug sensitivity of breast-ovarian cancer syndrome related tumors: preclinical evidence (Continued)
Drew et al. [39] AG014699 (PARP inhibitor) was highly cytotoxic against BRCA2-deficient CAPAN1 pancreatic cancer cells, as
determined by a clonogenic assay. AG014699 and carboplatin efficiently inhibited growth of CAPAN1-derived
tumor xenografts, with the most pronounced effect while using combination of these drugs.
Kortmann et al. [40] BRCA2-deficient ovarian cancer xenografts showed marked response to olaparib, carboplatin, and olaparib plus
carboplatin, whereas BRCA2-proficient xenografts responded only to carboplatin and olaparib plus carboplatin.
PALB2
Villarroel et al. [97] High sensitivity of PALB2-deficient xenografted pancreatic tumor to mitomycin C and cisplatin but not to
gemcitabine.
Other genes
McCabe et al. [93] RNA-interference driven inhibition of NBN (NBS1), CHEK2 or some other genes involved in homologous
recombination increased sensitivity of cultured cells to PARP inhibitors, as determined by cell survival assays.
Bartz et al. [29] BRIP1 inhibition strongly increased sensitivity of HeLa cells to cisplatin, as revealed by siRNA screen.
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Study Study design and main findings
1
Breast cancer
Kloos et al. [156]; Delagoge et al.
[65]
15 BRCA1 carriers, 5 BRCA2 carriers and 57 matched controls were treated by anthracycline-based neoadjuvant
therapy. Objective responses in 100%, 80%, 63% and pCR in 53%, 0% and 14%, respectively.
Chappuis et al. [66]; Wong Wong
Keet et al. [71]
7 BRCA1 and 4 BRCA2 carriers were treated by 3-4 cycles of anthracycline-based neoadjuvant therapy, 10 (91%)
of them achieved cCR; pCR were documented in 4 (44%) out of 9 evaluable cases. 27 patients served as
controls: cCR and pCR were detected in 8 (30%) and 1 (4%) patients, respectively.
These patients were followed for a median period of 7 years. Among complete clinical responders, only 1
(17%) out 6 BRCA1 carriers but 3 (75%) out of 4 BRCA2 carriers died of breast cancer.
Warner et al. [67] Rapid radiological disappearance and complete pathological response in a BRCA1 carrier treated by
neoadjuvant FEC.
Petit et al. [72] 55 triple-negative BC treated by neoadjuvant FEC. The subgroup of BRCA1 carriers showed lower pCR rate (2/
12, 17%) than overall (23/55, 42%).
Chrisanthar et al. [94] 2/3 (67%) CHEK2 mutation carriers as compared to 8/104 (8%) non-carriers progressed on neoadjuvant
epirubicin monotherapy for locally advanced breast cancer.
Hubert et al. [68] 15 BRCA1 and 7 BRCA2 stage III breast cancers were treated by anthracycline-based neoadjuvant therapy. cCR
in 6/15 (40%) and 1/7 (14%), pCR in 2/15 (13%) and 0 patients, respectively.
Melichar et al. [157] Case report on 2 related BRCA1 carriers, whose tumor demonstrated pCR upon dose dense AC and sequential
weekly paclitaxel.
Wysocki et al. [75] 19 non-responders to docetaxel have been analyzed; 5 (26%) of them turned out to be BRCA1 carriers.
Fong et al. [102] Phase I study dose escalation study for olaparib. 3 BRCA2-related chemotherapy refractory breast cancer
patients were evaluable for the treatment efficacy; 1 OR and 1 SD were observed. No responses in BRCA-
mutation-negative cases included in the study.
Fourquet et al. [69] Higher rate of cCR to anthracycline-based neoadjuvant therapy in BRCA1/2-carriers (15/33, 46%) vs. non carriers
(7/41, 17%)
Huang et al. [80] Case report: metastatic breast cancer in a BRCA2-carrier was treated by several regimens of high dose therapy
(epirubicin, alkylating agents, cisplatin, other cytotoxic drugs); CR with duration of 11+ years was observed.
Kriege et al. [73] 93 BRCA1 and 28 BRCA2 carriers received 1
st-line chemotherapy (mainly anthracycline-based or CMF (CMF-like))
for the treatment of metastatic disease. Sporadic cases (n = 121) were used as a control. Marginally improved
outcomes in BRCA1 carriers: OR: 66% vs. 50%; median PFS: 7.6 vs. 6.7 months; median OS: 15.0 vs. 13.6 months;
significantly improved outcomes in BRCA2 carriers: OR: 89% vs. 50%; median PFS: 11.4 vs. 6.7 months; median
OS: 19.3 vs. 13.6 months.
Rhiem et al. [158] Case report: major response of heavily pretreated metastatic BRCA1-related cancer to the combination of
cisplatin and gemcitabine, with the duration > 6 months.
Vollebergh et al. [81] Long term outcome of high dose therapy (carboplatin, thiotepa and cyclophosphamide) is analyzed in 40
patients with metastatic breast cancer. 6 patients remained on complete remission at the time of the analysis
(56+ - 150+ months); all these 6 patients demonstrated chromosomal imbalances characteristic for BRCA1-
related cancers. Complete long term responders included 1 out of 2 BRCA1- and 1 out of 2 BRCA2-carriers.
Byrski et al. [70,159,160] 102 BRCA1 carriers treated by neoadjuvant chemotherapy. pCR in 1/14 (7%) women receiving CMF, 2/25 (8%)
patients exposed to doxorubicin and docetaxel, 11/51 (22%) cases treated by AC or FAC, 10/12 (83%) women
receiving cisplatin.
Moiseyenko et al. [74] Case-report: lack of response of a chemonaive BRCA1-related cancer to the 1
st line epirubicin-docetaxel
combination, than major response to the 2
nd line single-agent cisplatin.
Silver et al. [78] 28 stage II or III triple-negative breast cancers were treated by 4 cycles of neoadjuvant cisplatin monotherapy.
Two BRCA1-carriers were included in the study, and both achieved pCR.
Kriege et al. [76] 32 BRCA1 carriers, 13 BRCA2 carriers and 95 controls treated by taxane monotherapy or taxane-trastuzumab
combination. Inferior results in BRCA1 carriers (OR rate = 23% vs. 38%; PD in 60% vs. 19%; median PFS = 2.2 vs.
4.9 months); this difference retained significance only in hormone receptor-negative cases, while hormone
receptor-positive tumors showed similar response rates and PFS. BRCA2 carriers: higher OR rate (89% vs. 38%),
similar median PFS (7.1 vs. 5.7 months).
Tutt et al. [82] BRCA1- and BRCA2-related metastatic breast cancers, with at least 1 prior chemotherapy regimen, treated by
high-dose (n = 27) or low-dose (n = 27) olaparib. OR in 41% and 22%; SD in 44% and 44%; median PFS = 5.7
and 3.8 months.
Sokolenko et al. [104] 5 BLM-related breast cancers treated by conventional neoadjuvant chemotherapy; 3 patients showed nearly
complete pathologic response, and 2 remaining women demonstrated partial response.
Ovarian cancer
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Cass et al. [83] 34 BRCA carriers (22 BRCA1 and 12 BRCA2) vs. 37 non-carriers were included in the study; 29 vs. 25 had stage
III-IV disease and were therefore considered for the analysis of treatment outcome; 22 vs. 18 received paclitaxel
plus carboplatin, and 7 vs. 7 were treated by cyclophosphamide plus carboplatin. BRCA1/2 carriers
demonstrated higher OR rate (21/24 (88%) vs. 9/19 (47%)) and longer median OS (91 vs. 54 months) than non-
carriers.
Tan et al. [84] Therapy response was compared in 22 BRCA carriers (17 BRCA1 and 5 BRCA2) vs. 44 non carriers matched by
stage, histological subtype, age at diagnosis and year at diagnosis. Higher sensitivity to platinum-based therapy
in the 1
st line (OR: 96% vs. 59%; CR: 82% vs. 43%), 2
nd line (92% vs. 41%) and 3
rd line treatment (100% vs. 14%);
longer median OS (8.4 vs. 2.9 years).
Fong et al. [102] Phase I study dose escalation study for olaparib. 15 BRCA-related (14 BRCA1 and 1 BRCA2) chemotherapy
refractory ovarian cancer patients were evaluable for treatment efficacy; 8 (53%) OR and 1 (7%) SD were
observed. No responses in BRCA-mutation-negative cases included in the study.
Leunen et al. [161] 6 patients with relapsed BRCA-related ovarian cancer, treated by multiple lines of therapy including dose-dense
paclitaxel-carboplatin; all patients responded to the therapy; median OS = 37 months as compared to 18
months in the historical control.
Melichar et al. [86] Case report on a BRCA1-related ovarian cancer relapsed after prolonged post-surgical paclitaxel-carboplatin
therapy; each of 4 consequent relapses showed complete response to paclitaxel-cisplatin combination.
Audeh et al. [87] BRCA1- and BRCA2-related recurrent ovarian cancers, with at least 1 prior chemotherapy regimen, treated by
high-dose (n = 33) or low-dose (n = 24) olaparib. OR in 33% and 15%; SD in 36% and 29%; median duration
of response = 290 and 269 days.
Fong et al. [88] Phase I dose escalation and single-stage expansion trial for olaparib, given to 50 patients (including 41 BRCA1
and 7 BRCA2 carriers) with advanced ovarian cancer, previously treated by platinum based therapy. OR in 20
(40%) and SD in 3 (6%) patients. Median duration of response = 28 weeks. Strong correlation with platinum
sensitivity of the disease.
Moiseyenko et al. [74] Complete clinical response and nearly-complete pathological response of bulky tumor treated by 5 cycles of
single-agent cisplatin.
Vencken et al. [85] 93 BRCA1-related, 13 BRCA2-related and 222 sporadic cancers analyzed for response to the 1
st line
chemotherapy. CR or no evidence for disease: 87%, 92% and 71%, respectively; PD: 2%, 0% and 15%; median
PFS: 2.1, 5.6 and 1.3 years; median OS: 5.9, > 10 and 2.9 years. Similar response rates in patients receiving
combination of platinum and paclitaxel vs. those treated by platinum-based therapy without paclitaxel.
Pancreatic cancer
Chalasani et al. [98] Case report on a BRCA2-related pancreatic adenocarcinoma. 1
st line therapy included combination of
gemcitabine with experimental alkylating agent, and resulted in a major tumor response. Then alkylating agent
was discontinued due to toxicity, and PD was observed on single-agent gemcitabine. Experimental
antiangiogenic drug was given in the 2
nd line without any effect. 3
rd line therapy included mitomycin C plus
capecitabine, and again led to a major tumor response.
James et al. [99] Case report on a BRCA2-related, KRAS wild-type pancreatic adenocarcinoma. Prolonged SD (56+ months) upon
multiple lines of chemotherapy (combination of docetaxel, capecitabine and gemcitabine; then irinotecan
monotherapy; then irinotecan plus cetuximab; then mitomycin C plus oxaliplatin; then mitomycin C plus
irinotecan).
Villarroel et al. [97] Case report on a PALB2-related pancreatic adenocarcinoma, which progressed under 1
st line single-agent
gemcitabine, but showed major response after mitomycin C administration. Later mitomycin C was replaced
by cisplatin due to toxicity of the former. The patient remains asymptomatic for 36+ months.
Fogelman et al. [100] Case report on a BRCA2-related relapsed pancreatic adenocarcinoma, which rapidly regressed upon the
combination of gemcitabine and iniparib. Subsequent surgery revealed a complete pathologic response.
Other cancers
Fong et al. [102] Phase I study dose escalation study for olaparib. 1 BRCA2-related castration-resistant prostate cancer patient
was included in the study; he demonstrated significant, durable marker response as well as resolution of bone
metastases. No responses in BRCA-mutation-negative cases.
Moule et al. [101] Case report: complete response lasting for 10+ years in a BRCA2 carrier, whose advanced non-small cell lung
cancer was treated by the combination of mitomycin C, cisplatin and vincristine.
Vesprini et al. [103] Case report describing a patient with metastatic BRCA2-related prostate cancer, who was treated by cisplatin
after becoming insensitive to androgen ablation. Cisplatin therapy resulted in normalization of prostate-specific
antigen level and symptomatic relief for period of 8 months; docetaxel was administered after the disease
progression, and also led to an evident tumor response.
1Drug combinations: CMF: cyclophosphamide, methotrexate and fluorouracil; AC: doxorubicin and cyclophosphamide; FAC: 5-fluorouracil, doxorubicin and
cyclophosphamide; FEC: 5-fluorouracil, epirubicin and cyclophosphamide.
Treatment outcomes: OR: objective response; PR: partial response; CR: complete response; cCR: clinical complete response; pCR: pathological complete response;
SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival.
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frame and therefore function of the corresponding pro-
tein [61,79]. One may expect that the newly acquired
BRCA1 proficiency will result in sensitization of the can-
cer cells to estrogen antagonists and taxanes [74].
There are a few case reports on the extremely success-
ful use of high dose chemotherapy in metastatic BRCA-
related BC. Since BRCA-deficient BC are particularly
sensitive to DNA damaging agents, use of intensive
cytotoxic treatment may provide additional benefit to
this category of patients. Furthermore, high dose therapy
is likely to counteract tumor adaptation to the drugs, e.
g. to induce rapid killing of cancer cells and therefore
decrease the probability of developing secondary
BRCA1-restoring mutations. It is also important to con-
sider that BRCA-driven cancers are often characterized
by young age at onset, i.e. the majority of these patients
would retain sufficient health conditions to qualify for a
risky medical intervention. Huang et al. [80] described a
patient with metastatic BRCA2-related BC, who was
treated by high dose chemotherapy and remains disease-
free for more than 11 years. Vollebergh et al. [81] pre-
sented long term outcomes for 40 metastatic BC
patients treated by high dose chemotherapy. 6 patients
remained on complete remission for 56+ - 150+
months, and all these 6 patients demonstrated chromo-
somal imbalances characteristic for BRCA1-related can-
cers. Complete long term responders included 1 out of
2 BRCA1- and 1 out of 2 BRCA2-carriers.
The only prospective clinical trial specifically designed
for BRCA carriers evaluated the efficacy of the PARP
inhibitor olaparib (AZD2281, KU0059436) [82]. The
study included metastatic breast cancer patients, who
progressed on the standard chemotherapy schemes.
When olaparib was given 400 mg twice daily, objective
response and disease stabilization were observed in 11/
27 (41%) and 12/27 (44%) patients, respectively. Median
progression-free survival approached to 5.7 months.
In agreement with preclinical findings, cisplatin and
olaparib clearly outperform conventional treatment
schemes when administered to BRCA1-driven BC cases.
However, both these drugs have limited duration of
response, so their use may require the addition of other
anticancer agents [31,33,38,39,59].
Ovarian cancer
BRCA-deficiency in cancer cell can be caused either by
germ-line mutation followed by the “second hit”,o rb y
somatic inactivation of the BRCA1 gene. BRCA-inactive
tumors constitute the minority of breast cancers (up to
10-15%), and are usually accumulated among family his-
tory positive or triple-negative cases. In contrast to BC,
the majority of ovarian carcinomas have signs of BRCA
inactivation, commonly defined in the literature as
“BRCAness” [9,15]. Frequent BRCA-deficiency in OC
appears to be a plausible explanation of the clinical suc-
cess of platinum-based schemes in the treatment of this
disease.
Three studies compared response to the standard che-
motherapeutic regimens in BRCA1/2- mutated vs.
sporadic OC cases [83-85]. These reports provide con-
sistent evidence for higher sensitivity of BRCA-driven
OC to platinum-containing treatments as compared to
the mutation-negative tumors. Interestingly, prolonged
tumor responses were documented both for taxane-free
schemes and for the combination of platinating drugs
with paclitaxel [83-86].
Two independent large trials evaluated the efficacy of
olaparib in BRCA-mutated OC patients, who experi-
enced prior chemotherapy [87,88]. Audeh et al. [87]
observed objective response in 33% and stable disease in
36% of women receiving olaparib at dose 400 mg twice
daily. Fong et al. [88] reported tumor response in 40%
and disease stabilization in 6% patients, respectively; as
expected, higher efficacy of olaparib was documented in
those cases, which retained sensitivity to platinum-based
therapy.
Other genes and other tumors
Hereditary BC research led to identification of several
genes other than BRCA1 and BRCA2. CHEK2 appears
to be the most studied gene of this class. It confers ele-
vated risk of breast cancer, while its heterozygous occur-
rence among ovarian cancer patients is not elevated
[89,90]. CHEK2-mutated BC frequently express estrogen
receptor [91,92]. Inactivation of CHEK2 by RNA-inter-
ference increased cell sensitivity to PARP inhibition
[93]. The only available clinical observation describes
BC progression in 2 out of 3 CHEK2 carriers, who were
treated by neoadjuvant single-agent epirubicin, while
this outcome was rare (8/104, 8%) in the non-carriers
[94].
PALB2 (Partner And Localizers of BRCA2) has been
proven to cause breast and pancreatic hereditary cancer
[95,96]. In agreement with BRCA2-related function of
the PALB2, pancreatic cancer xenografts obtained from
a PALB2 carrier demonstrated pronounced sensitivity to
cisplatin and mitomycin C [97]. Importantly, excellent
concordance between in vitro and clinical data was
observed for this patient: his poorly differentiated ductal
adenocarcinoma of the pancreas failed standard gemci-
tabine therapy, but demonstrated durable tumor
response after mitomycin C or cisplatin administration
[97]. Increased drug sensitivity of pancreatic tumors
obtained from BRCA2 carriers was described in several
other case reports [98-100]. Therefore, hereditary pan-
creatic cancers have clearly more favorable pattern of
drug response as compared to sporadic cases. Similarly,
excellent treatment effect lasting for more than 10 years
was documented for BRCA2-related advanced lung
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and vincristine [101]. Another BRCA2 carrier, who suf-
fered from castration-resistant prostate cancer, showed
durable marker response and resolution of bone metas-
tases after the administration of olaparib [102]. Vesprini
et al. [103] have described a case of metastatic BRCA2-
related prostate cancer, which was treated by cisplatin
after becoming insensitive to androgen ablation. This
therapy resulted in normalization of prostate-specific
antigen level and symptomatic relief for period of 8
months; docetaxel was administered after the disease
progression, and also led to an evident tumor response.
Sokolenko et al. [104] have recently revealed a role of
BLM gene mutations in hereditary predisposition to
breast cancer. This study included 5 patients treated by
conventional neoadjuvant therapy; nearly complete
pathological response was observed in 3 cases, while the
remaining 2 women showed partial reduction of the
tumor mass.
Preclinical data suggest specific drug sensitivity pat-
tern for the cells with inactivated NBN (NBS1) and
BRIP1 (FANCJ, BACH1) genes [29,93]. It may turn to be
difficult to validate these findings in the clinical setting,
due to rarity and population-specific distribution of
mutations in the mentioned genes.
Hereditary non-polyposis colorectal cancer
Hereditary non-polyposis colorectal cancer (HNPCC) is
caused by germ-line mutations in MLH1, MSH2, PMS2
and MSH6 genes. Virtually all tumors from HNPCC
mutation carriers are characterized by the defect of mis-
match repair (MMR), which is manifested by so-called
high-level microsatellite instability (MSI-H). MSI-H
occurs in up to 15% of colorectal cancers (CRC), how-
ever the majority of the microsatellite-unstable carcino-
mas are sporadic; hereditary CRC constitute
approximately one fifth of MSI-H cases and account for
only 2-3% of the total CRC incidence. Mutations in
HNPCC-related genes may also predispose to a number
of non-colonic tumors, including endometrial, gastric,
urothelial, ovarian and some other neoplasms [105,106].
Given the rarity of hereditary CRC and the require-
ment of expensive multigene test for its definite diagno-
sis, the collection of clinical series for this disease
represents a challenge. Instead, there is an intensive
research focusing on MSI-H tumors as a distinct CRC
entity; although sporadic and hereditary MSI-H CRC
tumors share essential bioclinical features, many experts
warn against combined analysis of these two tumor sub-
sets. It is emphasized, that while hereditary CRC affect
relatively young subjects, sporadic MSI-H cases are
accumulated among elderly patients. Hereditary CRC
arise due to mutational inactivation of the MLH1,
MSH2, PMS2 or MSH6; sporadic MSI-H tumors are
usually driven by methylation of the MLH1 gene promo-
ter that may be a consequence of wide-spread abnorm-
alities of epigenetic regulation ("methylator phenotype”).
For unknown reason, BRAF mutations occur only in
sporadic but not in hereditary MSI-H tumors [106,107].
Although MSI-H tumors tend to be poorly differen-
tiated, they are usually characterized by favorable disease
course. In particular, MSI-H tumors show relatively low
relapse rates after potentially curative surgery [108,109];
in accordance with this, only 4% of advanced CRC have
MSI-H phenotype [110]. As result, MSI-H cases are
exceptionally rare in trials involving metastatic CRC,
therefore the direct clinical assessment of their chemo-
sensitivity is highly complicated. The majority of treat-
ment response data for MSI-H cases is derived from the
adjuvant trials, where the reliable discrimination
between prognostic and predictive significance of a
given parameter is not always possible. Another critical
issue concerns technical aspects of determination of
microsatellite instability. The existing approaches for
detection of MSI-H phenotype are not fully standardized
and may be a subject of significant interlaboratory varia-
tions [111]. In particular, there is a debate concerning
the inclusion of dinucleotide microsatellite markers in
the “Bethesda panel”, which is frequently used for MSI-
H diagnosis [112]. Many opinion leaders insist, that only
mononucleotide markers (e.g., BAT26) allow to differ-
entiate between true MSI-H and irrelevant mutational
noise; hence, consideration of dinucleotide loci may
increase the frequency of false-positive MSI-H detection
and further compromise the conclusions of clinical trials
[111].
Sensitivity of MMR-deficient cells to various antican-
cer drugs has been a subject of multiple laboratory stu-
dies. It is important to acknowledge, that naturally
occurring MSI-H cancer cells have highly increased
mutation rate and therefore accumulate significant num-
ber of “secondary” genetic lesions; depending of the
spectrum of the target genes, these secondary lesions
m a ys u b s t a n t i a l l ym o d i f yt h er e s p o n s et ot r e a t m e n t
modalities [110,113]. Furthermore, inactivation of dis-
tinct MMR genes, e.g. MSH2 and MLH1,m a yr e s u l ti n
distinct patterns of chemosensitivity [114].
Most of preclinical studies point at resistance of MSI-
H cells to 5-fluorouracil (5-FU) [110,115]. MSI-H status
is also associated with low sensitivity to cisplatin, carbo-
platin, 6-thioguanine, however these compounds are
anyway not engaged in routine CRC treatment
[110,115-117]. While MMR-deficiency is associated with
non-response to cisplatin and carboplatin, the third pla-
tinating drug, oxaliplatin, does not require functional
MMR for its action [118]. Several studies have demon-
strated specific sensitivity of MSI-H cells to irinotecan;
it has been shown, that the response to topoisomerase I
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mutations in the double strand break response genes
MRE11 and RAD50 [113]. Screen of the library of cyto-
toxic drugs has identified methotrexate as selective inhi-
bitor of MSH2-deficient cells; MLH1-defective cells did
not show specific sensitivity to this compound [114].
Martin et al. [119,120] have recently identified PINK1
kinase and several DNA polymerases as potential targets
in cells with mutated MMR genes.
There is a good consensus in the literature that MSI-
H CRC patients do not benefit from 5-fluorouracil
based adjuvant therapy [121]. Some reports have sug-
gested even worse outcome in treated vs. non-treated
patients; it is speculated that ineffective adjuvant therapy
may compromise natural immune response to MSI-H
cells [110,122,123]. One of the adjuvant patient series
specifically included hereditary CRC cases, and also
demonstrated lack of benefit from 5-fluorouracil [124].
Given an improved prognosis of MSI-H tumors, it is
g e n e r a l l ya g r e e dt h a ta d j u v a n tt h e r a p ys h o u l db e
omitted for the stage II microsatellite unstable CRC
[110,125,126]. Combination of 5-fluorouracil with oxali-
platin has been recently incorporated in the guidelines
for adjuvant treatment of stage III CRC; as only a few
MSI-H patients with follow-up are currently available, it
is impossible to draw conclusions from the existing data
sets [127,128]. Trials with irinotecan did not qualify this
drug for the use in adjuvant setting; however, the analy-
sis of subset of patients with MSI-H has demonstrated,
that this specific category of CRC patients may benefit
from addition of irinotecan to fluorouracil and leucov-
orin [129].
Data on the use of chemotherapy for advanced MSI-H
CRC are limited by a few small studies. Liang et al.
[130] and Brueckl et al. [131] reported improved
response of microsatellite unstable CRC to the 5-fluor-
ouracil-based therapy. There is conflicting information
regarding the role of MSI status in determining
response to the combination of 5-fluorouracil and oxali-
platin combination [132-134]. Several reports suggested
increased response rate of MSI-H CRC to irinotecan
[135-137], although this statement was disputed by the
recent study of Kim et al. [138].
Burn et al. [139] analyzed the effect of aspirin and
resistant starch, given either alone or in combination,
on the occurrence of colorectal neoplasia in the MLH1,
MSH2 or MSH6 mutation carriers. Despite encouraging
preclinical and epidemiological evidence, neither of
these compounds influenced the risk of adenoma forma-
tion during the four years of the study.
Familial adenomatous polyposis
Familial adenomatous polyposis (FAP) is manifested by
multiple polyps, which cause severe gastrointestinal
symptoms and frequently progress into cancer lesions.
Classical FAP is caused by a dominant germ-line muta-
tion of the APC gene. Some patients bear an attenuated
form of this disease; mild manifestation of FAP may
indicate the involvement of another genetic lesion, i.e.
homozygous inactivation of MUTYH gene [140]. Devel-
opment of colonic adenomas usually involves activation
of cyclooxygenase 2. Clinical trial involving the specific
inhibitor of this enzyme, celecoxib (Onsenal), demon-
strated 28% reduction of the number of polyps and
30.7% reduction of the sum of polyp diameters in
patients receiving this drug at 400 mg twice daily for 6
months [141]. Based on the results of this trial, cele-
coxib has been approved for the treatment of FAP.
However the safety of its long term-use is questioned by
reports revealing elevated rate of cardiovascular events
in patients receiving therapeutically effective dose of the
drug [142]. Earlier studies demonstrated beneficial effect
of sulindac, a non-steroidal anti-inflammatory drug; the
results of these trials may be revisited, given that the
main adverse effect of this drug, i.e. gastrointestinal toxi-
city, is medically manageable [143].
Hereditary medullary thyroid cancer
Hereditary medullary thyroid cancer (MTC) is caused by
germ-line mutation in RET tyrosine kinase. It can be a
part of multiple endocrine neoplasia (MEN) type 2A
(MEN2A) or type 2B (MEN2B) syndromes, or manifest
as a single-organ lesion (familial medullary thyroid can-
cer, FMTC) [144]. A novel multitargeted tyrosine kinase
inhibitor vandetanib (ZD6474, Zactima) demonstrates
specific activity against mutated RET and inhibits
growth of RET-transformed cancer cells [145]. A clinical
trial involving 30 patients with hereditary MTC, who
received 300 mg vandetanib daily, demonstrated objec-
tive tumor response in 6/30 (20%) and disease stabiliza-
tion for more than 24 weeks in 16/30 (53%) cases,
respectively [146]. Precise measurement of the change of
tumor size revealed the reduction of the lesions in 25/30
(83%) patients; the estimated median progression-free
survival approached to 27.9 months [146]. Comparable
results were obtained in another trial, which utilized 100
mg daily dosage of this drug [147].
Sporadic phenocopies of hereditary cancers
Hereditary neoplasms make relatively little contribution
in the total cancer incidence. Nevertheless, advances in
the treatment of this category of tumors may have
broader practical implications, as many sporadic tumors
develop phenotype similar to hereditary cancers. This
issue was particularly intensively discussed in breast
cancer research, owing to substantial overlap between
BRCA1-related and triple-negative BC [14]. Given that
BRCA1 m a yb ei n a c t i v a t e dn o to n l yb yg e r m - l i n eb u t
also by somatic alterations, several investigations sug-
gested to use BRCA1 expression as predictive marker of
response to platinum-based and taxane-based therapy
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tion of consequences of either BRCA deficiency or other
critical defects of homologous recombination; in parti-
cular, it has been observed that tumors with presumably
impaired repair of DNA double-strand breaks show
characteristic pattern of acquired mutations [153,154].
Similarly to BRCA1, the mutations of RET oncogene are
observed not only in hereditary, but also in sporadic
medullary thyroid carcinomas; it is expected, that at
least a subset of RET-driven non-hereditary MTC
should respond to vandetanib therapy [144]. While for
some tumor types clinical experience is translated from
familial cancers to their phenocopies, the reverse flow is
observed in colorectal cancer research; as already men-
tioned above, virtually all data on drug response have
been obtained not on a genuine hereditary CRC, but on
its phenocopy, i.e. MSI-H tumors; this limitation has to
be considered by medical oncologists [106,107].
Conclusions and perspectives
Patients with hereditary tumors often benefit from dis-
tinct drugs as compared to sporadic cases. The detec-
tion of cancer-predisposing germ-line mutations among
the participants of clinical trials has rarely been consid-
ered, due to significant cost of genetic testing. Given the
rapidly increasing accessibility of DNA analysis, it is
foreseen that a large number of germ-line mutation car-
riers will be included in forthcoming trials and/or iden-
tified within retrospective collections of biological
material. The analysis of correlations between genotype
and drug response may substantially improve treatment
outcomes, both for hereditary cancer patients and for
subjects bearing phenocopies of familial tumors.
Abbreviations
AC: doxorubicin and cyclophosphamide; BC: breast cancer; CMF:
cyclophosphamide, methotrexate and fluorouracil; cCR: clinical complete
response; CR: complete response; CRC: colorectal cancer; FAC: 5-fluorouracil,
doxorubicin and cyclophosphamide; FAP: familial adenomatous polyposis;
FEC: 5-fluorouracil, epirubicin and cyclophosphamide; HNPCC: hereditary
non-polyposis colorectal cancer; HR: homologous recombination; MMR:
mismatch repair; MTC: medullary thyroid cancer; MSI-H: high-level
microsatellite instability; OC: ovarian cancer; OR: objective response; OS:
overall survival; PARP: poly (ADP-ribose) polymerase; pCR: pathological
complete response; PD: progressive disease; PFS: progression-free survival;
PR: partial response; SD: stable disease.
Acknowledgements
This work has been supported by the Russian Federation for Basic Research
(grants 10-04-92110, 10-04-92601, 11-04-00227), the Federal Agency for
Science and Innovations (contract 02.740.11.0780), the Commission of the
European Communities (grant PITN-GA-2009-238132) and the Government
of Moscow (grant 15/11).
Author details
1Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St.-
Petersburg, 197758, Russia.
2Department of Oncology, St.-Petersburg Medical
Academy for Postgraduate Studies, St.-Petersburg, 191015, Russia.
3Department of Medical Genetics, St.-Petersburg Pediatric Medical Academy,
St.-Petersburg, 194100, Russia.
Authors’ contributions
Both authors contributed to the literature search, data analysis and
manuscript preparation. Both authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 March 2011 Accepted: 6 August 2011
Published: 6 August 2011
References
1. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A: Effectiveness of
preventive interventions in BRCA1/2 gene mutation carriers: a
systematic review. Int J Cancer 2007, 121:225-231.
2. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C,
Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t’veer L, Tung N,
Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI,
Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR: Association of risk-
reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk
and mortality. JAMA 2010, 304:967-975.
3. Kurian AW: BRCA1 and BRCA2 mutations across race and ethnicity:
distribution and clinical implications. Curr Opin Obstet Gynecol 2010,
22:72-78.
4. Fasano J, Muggia F: Breast cancer arising in a BRCA-mutated
background: therapeutic implications from an animal model and drug
development. Ann Oncol 2009, 20:609-614.
5. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL: The role
of BRCA mutation testing in determining breast cancer therapy. Nat Rev
Clin Oncol 2010, 7:708-717.
6. van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P,
Cornelisse CJ, Verhoef S, Hogervorst FB, van’t Veer LJ, Nederlof PM:
Comparative genomic hybridization profiles in human BRCA1 and
BRCA2 breast tumors highlight differential sets of genomic aberrations.
Cancer Res 2005, 65:822-827.
7. Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM:
Genomic signature of BRCA1 deficiency in sporadic basal-like breast
tumors. Genes Chromosomes Cancer 2011, 50:71-81.
8. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S,
McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P,
Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS,
Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F,
Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B,
Bishop DT, Easton DF: Pathology of ovarian cancers in BRCA1 and BRCA2
carriers. Clin Cancer Res 2004, 10:2473-2481.
9. Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness’ in sporadic
cancers. Nat Rev Cancer 2004, 4:814-819.
10. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G,
Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T,
Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL,
O’Malley FP: BRCA2 mutation-associated breast cancers exhibit a
distinguishing phenotype based on morphology and molecular profiles
from tissue microarrays. Am J Surg Pathol 2007, 31:121-128.
11. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M,
Valgeirsdottir S, Eyfjord JE: Genomic profiling of breast tumours in
relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009,
11:R47.
12. Yarden RI, Papa MZ: BRCA1 at the crossroad of multiple cellular
pathways: approaches for therapeutic interventions. Mol Cancer Ther
2006, 5:1396-1404.
13. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J:
High incidence of protein-truncating TP53 mutations in BRCA1-related
breast cancer. Cancer Res 2009, 69:3625-3633.
14. Jaspers JE, Rottenberg S, Jonkers J: Therapeutic options for triple-negative
breast cancers with defective homologous recombination. Biochim
Biophys Acta 2009, 1796:266-280.
15. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD,
Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM,
McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB:
Somatic mutations in BRCA1 and BRCA2 could expand the number of
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 11 of 16patients that benefit from poly (ADP ribose) polymerase inhibitors in
ovarian cancer. J Clin Oncol 2010, 28:3570-3576.
16. Gudmundsdottir K, Ashworth A: The roles of BRCA1 and BRCA2 and
associated proteins in the maintenance of genomic stability. Oncogene
2006, 25:5864-5874.
17. Tutt A, Ashworth A: Can genetic testing guide treatment in breast
cancer? Eur J Cancer 2008, 44:2774-2780.
18. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE,
James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG,
Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP: Molecular basis
for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J
Natl Cancer Inst 2007, 99:1683-1694.
19. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-
Angulo AM, Hortobagyi GN, Arun BK: Clinical and pathologic
characteristics of patients with BRCA-positive and BRCA-negative breast
cancer. J Clin Oncol 2008, 26:4282-4288.
20. DeLigio JT, Zorio DA: Early growth response 1 (EGR1): a gene with as
many names as biological functions. Cancer Biol Ther 2009, 8:1889-1892.
21. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 up-regulation is
associated with repair-mediated resistance to cis-
diamminedichloroplatinum(II). Cancer Res 1998, 58(6):1120-1123.
22. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK: The
breast cancer susceptibility gene BRCA1 is required for subnuclear
assembly of Rad51 and survival following treatment with the DNA
cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903.
23. Lafarge S, Sylvain V, Ferrara M, Bignon YJ: Inhibition of BRCA1 leads to
increased chemoresistance to microtubule-interfering agents, an effect
that involves the JNK pathway. Oncogene 2001, 20:6597-6606.
24. Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D: The effect of
loss of Brca1 on the sensitivity to anticancer agents in p53-deficient
cells. Int J Oncol 2003, 22:1169-1173.
25. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG,
Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-
induced apoptosis. Cancer Res 2003, 63:6221-6228.
26. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML,
Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S: BRCA1 expression
modulates chemosensitivity of BRCA1-defective HCC1937 human breast
cancer cells. Br J Cancer 2003, 88:1285-1291.
27. Samouëlian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN,
Provencher DM, Mes-Masson AM: Chemosensitivity and radiosensitivity
profiles of four new human epithelial ovarian cancer cell lines exhibiting
genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
Cancer Chemother Pharmacol 2004, 54:497-504.
28. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA,
Shen D, Hruban RH, Kern SE: Functional defects in the fanconi anemia
pathway in pancreatic cancer cells. Am J Pathol 2004, 165:651-657.
29. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R,
Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M,
Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH,
Linsley PS: Small interfering RNA screens reveal enhanced cisplatin
cytotoxicity in tumor cells having both BRCA network and TP53
disruptions. Mol Cell Biol 2006, 26:9377-9386.
30. Xing D, Orsulic S: A mouse model for the molecular characterization of
brca1-associated ovarian carcinoma. Cancer Res 2006, 66:8949-8953.
31. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-
Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-
Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB,
Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC,
McGonigal TP, Meulbroek JA, Olson AM, Palma JP, et al: ABT-888, an orally
active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-
damaging agents in preclinical tumor models. Clin Cancer Res 2007,
13:2728-2737.
32. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van
de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O,
Schouten JP, Jonkers J, Borst P: Selective induction of chemotherapy
resistance of mammary tumors in a conditional mouse model for
hereditary breast cancer. Proc Natl Acad Sci USA 2007, 104:12117-12122.
33. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW,
Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A,
O’Connor MJ, Jonkers J: Selective inhibition of BRCA2-deficient mammary
tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008,
14:3916-3925.
34. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ,
Lee EY: Cancer stem cells contribute to cisplatin resistance in Brca1/p53-
mediated mouse mammary tumors. Cancer Res 2008, 68:3243-3250.
35. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-
Jones A, Smith GC, Martin NM, O’Connor M, Clarke AR: Poly(ADP-ribose)
polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-
mutant mammary tumors in vivo and delays tumor relapse in
combination with carboplatin. Cancer Res 2009, 69:3850-3855.
36. Santarosa M, Del Col L, Tonin E, Caragnano A, Viel A, Maestro R: Premature
senescence is a major response to DNA cross-linking agents in BRCA1-
defective cells: implication for tailored treatments of BRCA1 mutation
carriers. Mol Cancer Ther 2009, 8:844-854.
37. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T,
Bulotta A, Neri P, Caraglia M, Tagliaferri P: Loss of BRCA1 function
increases the antitumor activity of cisplatin against human breast cancer
xenografts in vivo. Cancer Biol Ther 2009, 8:648-653.
38. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H,
Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J: A high-
throughput pharmaceutical screen identifies compounds with specific
toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010, 16:99-108.
39. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S,
Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ,
Curtin NJ: Therapeutic potential of poly(ADP-ribose) polymerase inhibitor
AG014699 in human cancers with mutated or methylated BRCA1 or
BRCA2. J Natl Cancer Inst 2011, 103:334-346.
40. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A,
Cranston AN, O’Connor MJ, Huntsman DG, Wang Y, Gilks CB: Tumor
growth inhibition by olaparib in BRCA2 germline-mutated patient-
derived ovarian cancer tissue xenografts. Clin Cancer Res 2011, 17:783-791.
41. Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ,
West SC, Venkitaraman AR: Gross chromosomal rearrangements and
genetic exchange between nonhomologous chromosomes following
BRCA2 inactivation. Genes Dev 2000, 14:1400-1406.
42. Moynahan ME, Cui TY, Jasin M: Homology-directed dna repair,
mitomycin-c resistance, and chromosome stability is restored with
correction of a Brca1 mutation. Cancer Res 2001, 61:4842-4850.
43. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC,
Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE: In
vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status
of the tumor. Clin Cancer Res 2005, 11:7508-7515.
44. Yun J, Zhong Q, Kwak JY, Lee WH: Hypersensitivity of Brca1-deficient MEF
to the DNA interstrand crosslinking agent mitomycin C is associated
with defect in homologous recombination repair and aberrant S-phase
arrest. Oncogene 2005, 24:4009-4016.
45. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX: Multiple genetic
changes are associated with mammary tumorigenesis in Brca1
conditional knockout mice. Oncogene 2001, 20:7514-7523.
46. Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S,
Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C,
Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ,
Helleday T: 6-thioguanine selectively kills BRCA2-defective tumors and
overcomes PARP inhibitor resistance. Cancer Res 2010, 70:6268-6276.
47. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency
and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst
1998, 90:978-985.
48. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN:
BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced
DNA double-strand breaks via topoisomerase II. Cancer Res 2007,
67:7078-7081.
49. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C,
McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA,
Johnston PG, Harkin DP: BRCA1 and GADD45 mediated G2/M cell cycle
arrest in response to antimicrotubule agents. Oncogene 2001,
20:6123-6131.
50. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F: BRCA1
downregulation leads to premature inactivation of spindle checkpoint
and confers paclitaxel resistance. Cell Cycle 2006, 5:1001-1007.
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 12 of 1651. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S: BRCA1 modulates
malignant cell behavior, the expression of survivin and chemosensitivity
in human breast cancer cells. Int J Cancer 2009, 125:2820-2828.
52. Zhou C, Smith JL, Liu J: Role of BRCA1 in cellular resistance to paclitaxel
and ionizing radiation in an ovarian cancer cell line carrying a defective
BRCA1. Oncogene 2003, 22:2396-2404.
53. Tassone P, Blotta S, Palmieri C, Masciari S, Quaresima B, Montagna M,
D’Andrea E, Eramo OP, Migale L, Costanzo F, Tagliaferri P, Venuta S:
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer
cells to microtubule-interfering agents. Int J Oncol 2005, 26:1257-1263.
54. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O,
Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P,
Rottenberg S: Sensitivity and acquired resistance of BRCA1;p53-deficient
mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Cancer Res 2010, 70:1700-1710.
55. Rahden-Staroń I, Szumił M, Grosicka E, Kraakman van der Zwet M,
Zdzienicka MZ: Defective Brca2 influences topoisomerase I activity in
mammalian cells. Acta Biochim Pol 2003, 50:139-144.
56. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S,
Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient
tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005,
434:913-917.
57. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB,
Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP,
Smith GC, Ashworth A: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature 2005, 434:917-921.
58. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A: BRCA2-
deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly
(ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005,
4:934-936.
59. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO,
Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R,
Cranston A, O’Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of
BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone
and in combination with platinum drugs. Proc Natl Acad Sci USA 2008,
105:17079-17084.
60. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA: Nanoparticle-
mediated delivery of siRNA targeting Parp1 extends survival of mice
bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc
Natl Acad Sci USA 2011, 108:745-750.
61. Ashworth A: Drug resistance caused by reversion mutation. Cancer Res
2008, 68:10021-10023.
62. Underhill C, Toulmonde M, Bonnefoi H: A review of PARP inhibitors: from
bench to bedside. Ann Oncol 2011, 22:268-279.
63. Narod SA: BRCA mutations in the management of breast cancer: the
state of the art. Nat Rev Clin Oncol 2010, 7:702-707.
64. Foulkes WD, Goffin J, Brunet JS, Bégin LR, Wong N, Chappuis PO:
Tamoxifen may be an effective adjuvant treatment for BRCA1-related
breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst
2002, 94:1504-1506.
65. Delaloge S, Pélissier P, Kloos I, Bressac de Paillerets B, Mathieu MC,
Chompret A, Noguès C, Lortholary A, Piketty AC, Spielmann M: BRCA1-
linked breast cancer (BC) is highly more chemosensitive than its BRCA2-
linked or sporadic counterparts. Ann Oncol 2002, 13(Suppl 5):34.
66. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN,
Foulkes WD: A significant response to neoadjuvant chemotherapy in
BRCA1/2 related breast cancer. J Med Genet 2002, 39:608-610.
67. Warner E, Trudeau M, Holloway C: Sensitivity of BRCA-1-related breast
cancer to neoadjuvant chemotherapy: practical implications. Breast J
2003, 9:507-508.
68. Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L:
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related
stage III breast cancer. Fam Cancer 2009, 8:173-177.
69. Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B, Institut
Curie Breast Cancer Study Group; Institut Curie Breast Ovary Cancer Risk
Study Group: Familial breast cancer: clinical response to induction
chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am
J Clin Oncol 2009, 32:127-131.
70. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M,
Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S:
Pathologic complete response rates in young women with BRCA1-
positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol
2010, 28:375-379.
71. Wong Wong Keet A, Al-Rafae M, Chappuis PO, Brunet JS, Ghadirian P,
Foulkes WD: Long-term outcome after neo-adjuvant chemotherapy for
breast cancer in BRCA1/2 carriers. Int J Cancer 2009, 125:2236-2238.
72. Petit T, Wilt M, Rodier J, Muller D, Ghnassia J, Dufour P, Fricker J: Are BRCA1
mutations a predictive factor for anthracycline-based neoadjuvant
chemotherapy response in triple-negative breast cancers? J Clin Oncol
2007, 25(Suppl):abstract 580.
73. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB,
Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den
Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG: Sensitivity
to first-line chemotherapy for metastatic breast cancer in BRCA1 and
BRCA2 mutation carriers. J Clin Oncol 2009, 27:3764-3771.
74. Moiseyenko VM, Protsenko SA, Brezhnev NV, Maximov SY, Gershveld ED,
Hudyakova MA, Lobeiko OS, Gergova MM, Krzhivitskiy PI, Semionov II,
Matsko DE, Iyevleva AG, Sokolenko AP, Sherina NY, Kuligina ESh,
Suspitsin EN, Togo AV, Imyanitov EN: High sensitivity of BRCA1-associated
tumors to cisplatin monotherapy: report of two cases. Cancer Genet
Cytogenet 2010, 197:91-94.
75. Wysocki PJ, Korski K, Lamperska K, Zaluski J, Mackiewicz A: Primary
resistance to docetaxel-based chemotherapy in metastatic breast cancer
patients correlates with a high frequency of BRCA1 mutations. Med Sci
Monit 2008, 14:SC7-SC10.
76. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH,
Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C: The
efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1
and BRCA2 mutation carriers. Cancer 2011.
77. Imyanitov EN: Breast cancer therapy for BRCA1 carriers: moving towards
platinum standard? Hered Cancer Clin Pract 2009, 7:8.
78. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N,
Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD,
Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW,
Winer EP, Garber JE: Efficacy of neoadjuvant Cisplatin in triple-negative
breast cancer. J Clin Oncol 2010, 28:1145-1153.
79. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T: Secondary
BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum
resistance. Cancer Res 2008, 68:2581-2586.
80. Huang F, Kushner YB, Langleben A, Foulkes WD, Medscape: Eleven years
disease-free: role of chemotherapy in metastatic BRCA2-related breast
cancer. Nat Rev Clin Oncol 2009, 6:488-492.
81. Vollebergh MA, Nederlof PM, Wessels LF, Schmidt MK, Joosse SA, van
Beers E, Froklage F, Holtkamp M, Schrama JG, Wesseling J, Hauptmann M,
de Bruin M, Rodenhuis S, Linn SC: Predicting response to alkylating
chemotherapy in breast cancer patients using array comparative
genomic hybridization. Cancer Res 2009, 69(Suppl 1):abstract 6050.
82. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN,
Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G,
Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
advanced breast cancer: a proof-of-concept trial. Lancet 2010,
376:235-244.
83. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY: Improved
survival in women with BRCA-associated ovarian carcinoma. Cancer 2003,
97:2187-2195.
84. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-
Jones A, Norman A, Kaye SB, Gore ME: “BRCAness” syndrome in ovarian
cancer: a case-control study describing the clinical features and
outcome of patients with epithelial ovarian cancer associated with
BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-5536.
85. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME,
Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C:
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian
cancer patients after first-line chemotherapy compared with sporadic
ovarian cancer patients. Ann Oncol 2011, 22:1346-1352.
86. Melichar B, Fridrichová P, Tomsová M, Malírová E: Repeat chemosensitivity
of epithelial ovarian carcinoma in a BRCA1 mutation carrier to
paclitaxel/platinum combination chemotherapy. Eur J Gynaecol Oncol
2009, 30:323-325.
87. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-
McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK,
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 13 of 16Matulonis U, Wickens M, Tutt A: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010,
376:245-251.
88. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De
Greve J, Lubinski J, Shanley S, Messiou C, A’Hern R, Tutt A, Ashworth A,
Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB: Poly(ADP)-ribose
polymerase inhibition: frequent durable responses in BRCA carrier
ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010,
28:2512-2519.
89. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG:
CHEK2*1100delC genotyping for clinical assessment of breast cancer
risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin
Oncol 2008, 26:542-548.
90. Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG,
Gorodnova TV, Zaitseva OA, Yatsuk OS, Togo AV, Tkachenko NN,
Shiyanov GA, Lobeiko OS, Krylova NY, Matsko DE, Maximov SY,
Urmancheyeva AF, Porhanova NV, Imyanitov EN: High frequency of BRCA1,
but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian
cancer patients. Hered Cancer Clin Pract 2009, 7:5.
91. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J,
Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P,
Tollenaar RA, Klijn JG: Tumour characteristics and prognosis of breast
cancer patients carrying the germline CHEK2*1100delC variant. J Med
Genet 2004, 41:731-735.
92. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A,
Górski B, Wokołrczyk D, Masojć B, Narod SA, Lubiński J: Estrogen receptor
status in CHEK2-positive breast cancers: implications for
chemoprevention. Clin Genet 2009, 75:72-78.
93. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S,
O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A: Deficiency in
the repair of DNA damage by homologous recombination and
sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006,
66:8109-8115.
94. Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S,
Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR,
Lønning PE: CHEK2 mutations affecting kinase activity together with
mutations in TP53 indicate a functional pathway associated with
resistance to epirubicin in primary breast cancer. PLoS One 2008, 3:e3062.
95. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC,
Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A,
Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR,
Goggins M, Klein AP: Exomic sequencing identifies PALB2 as a pancreatic
cancer susceptibility gene. Science 2009, 324:217.
96. Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M,
Christiansen H, Rave-Fränk M, Dörk T, Imyanitov EN: PALB2 mutations in
German and Russian patients with bilateral breast cancer. Breast Cancer
Res Treat 2011, 126:545-550.
97. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S,
Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R,
Hidalgo M: Personalizing cancer treatment in the age of global genomic
analyses: PALB2 gene mutations and the response to DNA damaging
agents in pancreatic cancer. Mol Cancer Ther 2011, 10:3-8.
98. Chalasani P, Kurtin S, Dragovich T: Response to a third-line mitomycin C
(MMC)-based chemotherapy in a patient with metastatic pancreatic
adenocarcinoma carrying germline BRCA2 mutation. JOP 2008, 9:305-308.
99. James E, Waldron-Lynch MG, Saif MW: Prolonged survival in a patient
with BRCA2 associated metastatic pancreatic cancer after exposure to
camptothecin: a case report and review of literature. Anticancer Drugs
2009, 20:634-8.
100. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F,
Abbruzzese JL: Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in
BRCA2-associated pancreatic cancer. Anticancer Res 2011, 31:1417-1420.
101. Moule R, Sohaib A, Eeles R: Dramatic response to platinum in a patient
with cancer with a germline BRCA2 mutation. Clin Oncol (R Coll Radiol)
2009, 21:444-447.
102. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P,
Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB,
Schellens JH, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in
tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
103. Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S,
Bristow RG: The therapeutic ratio is preserved for radiotherapy or
cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J
2011, 5:E31-E35.
104. Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV,
Abysheva SN, Suspitsin EN, Kuligina ESh, Gorodnova TV, Pfeifer W, Togo AV,
Turkevich EA, Ivantsov OA, Voskresenskiy DV, Dolmatov GD, Bit-Sava EM,
Matsko DE, Semiglazov VF, Fichtner I, Larionov AA, Kuznetsov SG,
Antoniou AC, Imyanitov EN: High prevalence and breast cancer
predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int
J Cancer .
105. Boland CR, Goel A: Microsatellite instability in colorectal cancer.
Gastroenterology 2010, 138:2073-2087.
106. Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable
evidence. Nat Rev Clin Oncol 2010, 7:153-162.
107. Clark AJ, Barnetson R, Farrington SM, Dunlop MG: Prognosis in DNA
mismatch repair deficient colorectal cancer: are all MSI tumours
equivalent? Fam Cancer 2004, 3:85-91.
108. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite
instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.
109. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E: Microsatellite
instability as a marker of prognosis and response to therapy: a meta-
analysis of colorectal cancer survival data. Eur J Cancer 2010,
46:2788-2798.
110. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A: Mismatch
repair deficient colorectal cancer in the era of personalized treatment.
Nat Rev Clin Oncol 2010, 7:197-208.
111. Laghi L, Bianchi P, Malesci A: Differences and evolution of the methods
for the assessment of microsatellite instability. Oncogene 2008,
27:6313-6321.
112. Perucho M: Correspondence re: C.R. Boland et al., A National Cancer
Institute workshop on microsatellite instability for cancer detection and
familial predisposition: development of international criteria for the
determination of microsatellite instability in colorectal cancer. Cancer
Res., 58: 5248-5257, 1998. Cancer Res 1999, 59:249-256.
113. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J,
Tabernero J: Microsatellite instability due to hMLH1 deficiency is
associated with increased cytotoxicity to irinotecan in human colorectal
cancer cell lines. Br J Cancer 2008, 99:1607-1612.
114. Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A:
Methotrexate induces oxidative DNA damage and is selectively lethal to
tumour cells with defects in the DNA mismatch repair gene MSH2.
EMBO Mol Med 2009, 1:323-337.
115. Valentini AM, Armentano R, Pirrelli M, Caruso ML: Chemotherapeutic
agents for colorectal cancer with a defective mismatch repair system:
the state of the art. Cancer Treat Rev 2006, 32:607-618.
116. Papouli E, Cejka P, Jiricny J: Dependence of the cytotoxicity of DNA-
damaging agents on the mismatch repair status of human cells. Cancer
Res 2004, 64:3391-3394.
117. Yamane K, Schupp JE, Kinsella TJ: BRCA1 activates a G2-M cell cycle
checkpoint following 6-thioguanine-induced DNA mismatch damage.
Cancer Res 2007, 67:6286-6292.
118. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehmé A, Christen RD,
Haas M, MacLeod CL, Howell SB: In vitro and in vivo resistance to
cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997,
57:1841-1845.
119. Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A: Parallel high
throughput RNA interference screens identify PINK1 as a potential
therapeutic target for the treatment of DNA mismatch repair deficient
cancers. Cancer Res 2011, 71:1836-1848.
120. Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y,
Oka S, Kay E, Lord CJ, Ashworth A: DNA polymerases as potential
therapeutic targets for cancers deficient in the DNA mismatch repair
proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
121. des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B:
Does microsatellite instability predict the efficacy of adjuvant
chemotherapy in colorectal cancer? A systematic review with meta-
analysis. Eur J Cancer 2009, 45:1890-1896.
122. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM,
Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M,
Gallinger S: Tumor microsatellite-instability status as a predictor of
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 14 of 16benefit from fluorouracil-based adjuvant chemotherapy for colon
cancer. N Engl J Med 2003, 349:247-257.
123. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR,
French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M,
Zaniboni A, Seitz JF, Sinicrope F, Gallinger S: Defective mismatch repair as
a predictive marker for lack of efficacy of fluorouracil-based adjuvant
therapy in colon cancer. J Clin Oncol 2010, 28:3219-3226.
124. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH,
Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H,
Vasen HF: Survival after adjuvant 5-FU treatment for stage III colon
cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004,
109:468-471.
125. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability
in sporadic colon cancers. Curr Opin Oncol 2009, 21:369-373.
126. de la Chapelle A, Hampel H: Clinical relevance of microsatellite instability
in colorectal cancer. J Clin Oncol 2010, 28:3380-3387.
127. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH,
Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY,
Chun HK, Park YS: Clinical impact of microsatellite instability in colon
cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol
2010, 66:659-667.
128. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A,
Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of
p53 expression and microsatellite instability on stage III colon cancer
disease-free survival in patients treated by 5-fluorouracil and leucovorin
with or without oxaliplatin. Ann Oncol 2010, 21:772-780.
129. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B,
Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M:
Microsatellite instability predicts improved response to adjuvant therapy
with irinotecan, fluorouracil, and leucovorin in stage III colon cancer:
Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009,
27:1814-1821.
130. Liang JT, Huang KC, Lai HS, Lee PH, Cheng YM, Hsu HC, Cheng AL, Hsu CH,
Yeh KH, Wang SM, Tang C, Chang KJ: High-frequency microsatellite
instability predicts better chemosensitivity to high-dose 5-fluorouracil
plus leucovorin chemotherapy for stage IV sporadic colorectal cancer
after palliative bowel resection. Int J Cancer 2002, 101:519-525.
131. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, Merkel S,
Schaber S, Boxberger F, Kirchner T, Hohenberger W, Hahn EG, Wein A:
Relationship between microsatellite instability, response and survival in
palliative patients with colorectal cancer undergoing first-line
chemotherapy. Anticancer Res 2003, 23:1773-1777.
132. des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X,
Le Toumelin P, Uzzan B, Perret GY, Morere JF, Breau JL, Fagard R,
Schischmanoff PO: Microsatellite instability and sensitivitiy to FOLFOX
treatment in metastatic colorectal cancer. Anticancer Res 2007,
27:2715-2719.
133. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D,
Tannapfel A, Arkenau H, Hahn SA, Schmoll SH, Porschen R, Schmiegel W,
Graeven U, AIO Colorectal Study Group: Predictive and prognostic value
of microsatellite instability in patients with advanced colorectal cancer
treated with a fluoropyrimidine and oxaliplatin containing first-line
chemotherapy. A report of the AIO Colorectal Study Group. Int J
Colorectal Dis 2008, 23:1033-1039.
134. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH,
Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK,
Lee WY, Park YS: The effect of DNA mismatch repair (MMR) status on
oxaliplatin-based first-line chemotherapy as in recurrent or metastatic
colon cancer. Med Oncol 2010, 27:1277-1285.
135. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC,
Ducreux M, Praz F: Microsatellite instability is a predictive factor of the
tumor response to irinotecan in patients with advanced colorectal
cancer. Cancer Res 2003, 63:5738-5744.
136. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, Mitchell E, Fry R,
Boman B, Rose D, Fishel R, Curran W, Palazzo J: Microsatellite status and
cell cycle associated markers in rectal cancer patients undergoing a
combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy.
Anticancer Res 2004, 24:3161-3167.
137. Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S:
Mismatch repair status is a predictive factor of tumour response to 5-
fluorouracil and irinotecan chemotherapy in patients with advanced
colorectal cancer. Tumour Biol 2007, 28:212-220.
138. Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, Kim JH, Jang SJ,
Kim MJ, Yu CS, Kang YK, Kim JC, Kim TW: Association between deficient
mismatch repair system and efficacy to irinotecan-containing
chemotherapy in metastatic colon cancer. Cancer Sci 2011.
139. Burn J, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S,
Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ,
Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L,
Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R,
Lynch HT, Mathers JC, CAPP2 Investigators: Effect of aspirin or resistant
starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med
2008, 359:2567-2578.
140. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J
Rare Dis 2009, 4:22.
141. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB,
Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect
of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous
polyposis. N Engl J Med 2000, 342:1946-1952.
142. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J,
Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T,
Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B,
Sylwestrowicz T, Hawk ET, Adenoma Prevention with Celecoxib Study
Investigators: Five-year efficacy and safety analysis of the Adenoma
Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009, 2:310-321.
143. Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I,
Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ,
Hodgson S, Järvinen H, Mecklin JP, Møller P, Myrhøi T, Nagengast FM,
Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR,
Stormorken A, Tejpar S, Thomas HJ, et al: Guidelines for the clinical
management of familial adenomatous polyposis (FAP). Gut 2008,
57:704-713.
144. Frank-Raue K, Rondot S, Raue F: Molecular genetics and phenomics of
RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol 2010,
322:2-7.
145. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G,
Ryan AJ, Fontanini G, Fusco A, Santoro M: ZD6474, an orally available
inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET
kinases. Cancer Res 2002, 62:7284-7290.
146. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M,
Krebs A, Vasselli J, Schlumberger M: Vandetanib for the treatment of
patients with locally advanced or metastatic hereditary medullary
thyroid cancer. J Clin Oncol 2010, 10:767-772.
147. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R: Vandetanib (100
mg) in patients with locally advanced or metastatic hereditary
medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
148. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK,
Mullan PB, Johnston PG, Wilson RH, Harkin DP: BRCA1 mRNA expression
levels predict for overall survival in ovarian cancer after chemotherapy.
Clin Cancer Res 2007, 13:7413-7420.
149. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M,
Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Peñas R,
Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P,
Reguart N, Blanco R, Taron M: Customized treatment in non-small-cell
lung cancer based on EGFR mutations and BRCA1 mRNA expression.
PLoS One 2009, 4:e5133.
150. Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, Mora M, Celiz P,
Perez L, Rodríguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L,
Rosell R: BRCA1 mRNA expression and outcome to neoadjuvant
cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011,
22:139-144.
151. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C:
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome
of advanced non-small cell lung cancer. Med Oncol .
152. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K,
Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J: Correlation of
BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to
docetaxel-based first-line chemotherapy in patients with advanced/
metastatic non-small-cell lung cancer. Br J Cancer 2011, 104:316-323.
153. Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de
Vijver MJ, Nederlof PM, Jonkers J: BRCA1-mutated and basal-like breast
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 15 of 16cancers have similar aCGH profiles and a high incidence of protein
truncating TP53 mutations. BMC Cancer 2010, 10:654.
154. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van
Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EG, Schrama JG,
Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M,
Rodenhuis S, Linn SC: An aCGH classifier derived from BRCA1-mutated
breast cancer and benefit of high-dose platinum-based chemotherapy
in HER2-negative breast cancer patients. Ann Oncol 2011, 22:1561-1570.
155. Gallmeier E, Kern SE: Absence of specific cell killing of the BRCA2-
deficient human cancer cell line CAPAN1 by poly(ADP-ribose)
polymerase inhibition. Cancer Biol Ther 2005, 4:703-706.
156. Kloos I, Delaloge S, Chompret A, Noguès C, Bressac de Paillerets B,
Spielmann M: BRCA1/2-linked breast carcinoma is a highly
chemosensitive disease. Proc Am Soc Clin Oncol 2001, 20:abstract 1862.
157. Melichar B, Fridrichová P, Lukesová S, Mergancová J, Urminská H, Ryska A,
Foretová L: Pathological complete response after primary chemotherapy
in a mother and daughter with hereditary breast carcinoma: two case
reports. Eur J Gynaecol Oncol 2008, 29:188-190.
158. Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK:
Platinum sensitivity in a BRCA1 mutation carrier with advanced breast
cancer. Clin Oncol (R Coll Radiol) 2009, 21:448-450.
159. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J,
Gorski B, Lubinski J, Narod SA: Response to neoadjuvant therapy with
cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat
2009, 115:359-363.
160. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M,
Mierzwa T, Szwiec M, Wi÷niowski R, Siolek M, Narod SA, Lubinski J, Polish
Hereditary Breast Cancer Consortium: Response to neo-adjuvant
chemotherapy in women with BRCA1-positive breast cancers. Breast
Cancer Res Treat 2008, 108:289-296.
161. Leunen K, Cadron I, Van Gorp T, Amant F, Berteloot P, Neven P, Legius E,
Vergote I: Does paclitaxel-carboplatin chemotherapy in a dose-dense
regimen enhance survival of BRCA-related ovarian cancer patients? Int J
Gynecol Cancer 2009, 19:1501-154.
doi:10.1186/1897-4287-9-5
Cite this article as: Imyanitov and Moiseyenko: Drug therapy for
hereditary cancers. Hereditary Cancer in Clinical Practice 2011 9:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Imyanitov and Moiseyenko Hereditary Cancer in Clinical Practice 2011, 9:5
http://www.hccpjournal.com/content/9/1/5
Page 16 of 16